Loading…
Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making
In this prospective study (NCT03443609), we investigated the impact of 68Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response obtained for patients with prostate cancer (PCa) presenting a recurrence with a low rising PSA. One hundred thirty hormone-naive (PSA
Saved in:
| Published in: | The Prostate 2019-09, Vol.79 (13), p.1514-1522 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3 |
| container_end_page | 1522 |
| container_issue | 13 |
| container_start_page | 1514 |
| container_title | The Prostate |
| container_volume | 79 |
| creator | Rousseau, Caroline Le Thiec, Maelle Ferrer, Ludovic Rusu, Daniela Rauscher, Aurore Maucherat, Bruno Frindel, Mathieu Baumgartner, Pierre Fleury, Vincent Denis, Antoine Morel, Agnes Varmenot, Nicolas Debeaupuis, Emilie Campion, Loic Kraeber-Bodéré, Francoise |
| description | In this prospective study (NCT03443609), we investigated the impact of 68Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response obtained for patients with prostate cancer (PCa) presenting a recurrence with a low rising PSA.
One hundred thirty hormone-naive (PSA |
| doi_str_mv | 10.1002/pros.23869 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2275319007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275319007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3</originalsourceid><addsrcrecordid>eNo9kc1u1TAQRi1ERW8LGx4AzRIhpbUdJ47ZVbc_IBVxJS7ryLEnrSFxgu1Q9bH6hjht6crS6MwZ-fsIec_oCaOUn85hiie8bGr1imwYVbKgVFSvyYZySQvBSnlIjmL8RWnGKX9DDksmOKsruSEPu4CDG53X4R4CxmVIEaYeNNQNXOli9-PbGewu9qfbPax3ZjTJ_UWIabH34PzjMOmEYLQ3GGDWyaHPkjuXbmEyJhuz2CwhYAY-w7nTNz7vOAMzhn4K47oI2ltw46xNgslDusWgZ1xWyqJx0U2-GPVv52_ekoNeDxHfPb_H5OflxX77pbj-fvV1e3ZdGFZyWWgmJWfK8EpIW_NaoehUbRvaGFr3jWJWdbWwDWqjOqUbJphUVnelFCgqZcpj8vHJm3_4Z8GY2tFFg8OgPU5LbDmXVckUpTKjn55Qk8OIAft2Dm7MibaMtmtF7ZpS-1hRhj88e5duRPuC_u-k_AeI8I82</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275319007</pqid></control><display><type>article</type><title>Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making</title><source>Wiley</source><creator>Rousseau, Caroline ; Le Thiec, Maelle ; Ferrer, Ludovic ; Rusu, Daniela ; Rauscher, Aurore ; Maucherat, Bruno ; Frindel, Mathieu ; Baumgartner, Pierre ; Fleury, Vincent ; Denis, Antoine ; Morel, Agnes ; Varmenot, Nicolas ; Debeaupuis, Emilie ; Campion, Loic ; Kraeber-Bodéré, Francoise</creator><creatorcontrib>Rousseau, Caroline ; Le Thiec, Maelle ; Ferrer, Ludovic ; Rusu, Daniela ; Rauscher, Aurore ; Maucherat, Bruno ; Frindel, Mathieu ; Baumgartner, Pierre ; Fleury, Vincent ; Denis, Antoine ; Morel, Agnes ; Varmenot, Nicolas ; Debeaupuis, Emilie ; Campion, Loic ; Kraeber-Bodéré, Francoise</creatorcontrib><description>In this prospective study (NCT03443609), we investigated the impact of 68Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response obtained for patients with prostate cancer (PCa) presenting a recurrence with a low rising PSA.
One hundred thirty hormone-naive (PSA < 1.5 ng/mL) patients were enrolled. All patients received radical treatment. PET images were recorded 1 and 2 hours after injection of tracer and interpreted by two independent nuclear physicians. Six months after treatment ended, a PSA assay was requested to evaluate the therapeutic efficacy of the treatment based on PSMA results.
Data analysis for the first 52 included patients has been completed. 68Ga-PSMA-11-positive lesions were detected in 38/52 (73.1%) patients. Ninety-four lesions were detected as follows, 53/94 in lymph nodes (56.4%), 25/94 in bone (26.6%), and 12/94 into the prostate bed (12.7%). Detection rates were 58%, 81%, and 82% for serum PSA levels lower than 0.25 ng/mL, between 0.25 to ≤ 0.69 ng/mL and 0.70 ng/mL, respectively. As a result of the PSMA PET-CT, therapeutic management changed in 38/52 patients (73.1%). Patients had undetectable serum PSA levels after treatment guided by 68Ga-PSMA-11 PET-CT results in 10/52 (19.2%) cases and with a PSA decrease of over 60% in 18/52 (34.6%) patients.
Whilst our patient population presented a very low PSA level, preliminary results of the 68Ga-PSMA PET-CT study showed recurrence localization in more than half of the patients and this had a major clinical impact, as it resulted in treatment change in more than half of the patients and a significant decrease in PSA levels in a third of patients.</description><identifier>ISSN: 0270-4137</identifier><identifier>ISSN: 1097-0045</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.23869</identifier><identifier>PMID: 31421657</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Decision Making ; Gallium Isotopes ; Gallium Radioisotopes ; Humans ; Kallikreins - blood ; Male ; Membrane Glycoproteins ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - therapy ; Organometallic Compounds ; Positron Emission Tomography Computed Tomography - methods ; Prospective Studies ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - therapy ; Radiopharmaceuticals</subject><ispartof>The Prostate, 2019-09, Vol.79 (13), p.1514-1522</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3</citedby><cites>FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3</cites><orcidid>0000-0002-0455-0523</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31421657$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rousseau, Caroline</creatorcontrib><creatorcontrib>Le Thiec, Maelle</creatorcontrib><creatorcontrib>Ferrer, Ludovic</creatorcontrib><creatorcontrib>Rusu, Daniela</creatorcontrib><creatorcontrib>Rauscher, Aurore</creatorcontrib><creatorcontrib>Maucherat, Bruno</creatorcontrib><creatorcontrib>Frindel, Mathieu</creatorcontrib><creatorcontrib>Baumgartner, Pierre</creatorcontrib><creatorcontrib>Fleury, Vincent</creatorcontrib><creatorcontrib>Denis, Antoine</creatorcontrib><creatorcontrib>Morel, Agnes</creatorcontrib><creatorcontrib>Varmenot, Nicolas</creatorcontrib><creatorcontrib>Debeaupuis, Emilie</creatorcontrib><creatorcontrib>Campion, Loic</creatorcontrib><creatorcontrib>Kraeber-Bodéré, Francoise</creatorcontrib><title>Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>In this prospective study (NCT03443609), we investigated the impact of 68Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response obtained for patients with prostate cancer (PCa) presenting a recurrence with a low rising PSA.
One hundred thirty hormone-naive (PSA < 1.5 ng/mL) patients were enrolled. All patients received radical treatment. PET images were recorded 1 and 2 hours after injection of tracer and interpreted by two independent nuclear physicians. Six months after treatment ended, a PSA assay was requested to evaluate the therapeutic efficacy of the treatment based on PSMA results.
Data analysis for the first 52 included patients has been completed. 68Ga-PSMA-11-positive lesions were detected in 38/52 (73.1%) patients. Ninety-four lesions were detected as follows, 53/94 in lymph nodes (56.4%), 25/94 in bone (26.6%), and 12/94 into the prostate bed (12.7%). Detection rates were 58%, 81%, and 82% for serum PSA levels lower than 0.25 ng/mL, between 0.25 to ≤ 0.69 ng/mL and 0.70 ng/mL, respectively. As a result of the PSMA PET-CT, therapeutic management changed in 38/52 patients (73.1%). Patients had undetectable serum PSA levels after treatment guided by 68Ga-PSMA-11 PET-CT results in 10/52 (19.2%) cases and with a PSA decrease of over 60% in 18/52 (34.6%) patients.
Whilst our patient population presented a very low PSA level, preliminary results of the 68Ga-PSMA PET-CT study showed recurrence localization in more than half of the patients and this had a major clinical impact, as it resulted in treatment change in more than half of the patients and a significant decrease in PSA levels in a third of patients.</description><subject>Aged</subject><subject>Decision Making</subject><subject>Gallium Isotopes</subject><subject>Gallium Radioisotopes</subject><subject>Humans</subject><subject>Kallikreins - blood</subject><subject>Male</subject><subject>Membrane Glycoproteins</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Organometallic Compounds</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prospective Studies</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Radiopharmaceuticals</subject><issn>0270-4137</issn><issn>1097-0045</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo9kc1u1TAQRi1ERW8LGx4AzRIhpbUdJ47ZVbc_IBVxJS7ryLEnrSFxgu1Q9bH6hjht6crS6MwZ-fsIec_oCaOUn85hiie8bGr1imwYVbKgVFSvyYZySQvBSnlIjmL8RWnGKX9DDksmOKsruSEPu4CDG53X4R4CxmVIEaYeNNQNXOli9-PbGewu9qfbPax3ZjTJ_UWIabH34PzjMOmEYLQ3GGDWyaHPkjuXbmEyJhuz2CwhYAY-w7nTNz7vOAMzhn4K47oI2ltw46xNgslDusWgZ1xWyqJx0U2-GPVv52_ekoNeDxHfPb_H5OflxX77pbj-fvV1e3ZdGFZyWWgmJWfK8EpIW_NaoehUbRvaGFr3jWJWdbWwDWqjOqUbJphUVnelFCgqZcpj8vHJm3_4Z8GY2tFFg8OgPU5LbDmXVckUpTKjn55Qk8OIAft2Dm7MibaMtmtF7ZpS-1hRhj88e5duRPuC_u-k_AeI8I82</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Rousseau, Caroline</creator><creator>Le Thiec, Maelle</creator><creator>Ferrer, Ludovic</creator><creator>Rusu, Daniela</creator><creator>Rauscher, Aurore</creator><creator>Maucherat, Bruno</creator><creator>Frindel, Mathieu</creator><creator>Baumgartner, Pierre</creator><creator>Fleury, Vincent</creator><creator>Denis, Antoine</creator><creator>Morel, Agnes</creator><creator>Varmenot, Nicolas</creator><creator>Debeaupuis, Emilie</creator><creator>Campion, Loic</creator><creator>Kraeber-Bodéré, Francoise</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0455-0523</orcidid></search><sort><creationdate>201909</creationdate><title>Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making</title><author>Rousseau, Caroline ; Le Thiec, Maelle ; Ferrer, Ludovic ; Rusu, Daniela ; Rauscher, Aurore ; Maucherat, Bruno ; Frindel, Mathieu ; Baumgartner, Pierre ; Fleury, Vincent ; Denis, Antoine ; Morel, Agnes ; Varmenot, Nicolas ; Debeaupuis, Emilie ; Campion, Loic ; Kraeber-Bodéré, Francoise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Decision Making</topic><topic>Gallium Isotopes</topic><topic>Gallium Radioisotopes</topic><topic>Humans</topic><topic>Kallikreins - blood</topic><topic>Male</topic><topic>Membrane Glycoproteins</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Organometallic Compounds</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prospective Studies</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Radiopharmaceuticals</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rousseau, Caroline</creatorcontrib><creatorcontrib>Le Thiec, Maelle</creatorcontrib><creatorcontrib>Ferrer, Ludovic</creatorcontrib><creatorcontrib>Rusu, Daniela</creatorcontrib><creatorcontrib>Rauscher, Aurore</creatorcontrib><creatorcontrib>Maucherat, Bruno</creatorcontrib><creatorcontrib>Frindel, Mathieu</creatorcontrib><creatorcontrib>Baumgartner, Pierre</creatorcontrib><creatorcontrib>Fleury, Vincent</creatorcontrib><creatorcontrib>Denis, Antoine</creatorcontrib><creatorcontrib>Morel, Agnes</creatorcontrib><creatorcontrib>Varmenot, Nicolas</creatorcontrib><creatorcontrib>Debeaupuis, Emilie</creatorcontrib><creatorcontrib>Campion, Loic</creatorcontrib><creatorcontrib>Kraeber-Bodéré, Francoise</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rousseau, Caroline</au><au>Le Thiec, Maelle</au><au>Ferrer, Ludovic</au><au>Rusu, Daniela</au><au>Rauscher, Aurore</au><au>Maucherat, Bruno</au><au>Frindel, Mathieu</au><au>Baumgartner, Pierre</au><au>Fleury, Vincent</au><au>Denis, Antoine</au><au>Morel, Agnes</au><au>Varmenot, Nicolas</au><au>Debeaupuis, Emilie</au><au>Campion, Loic</au><au>Kraeber-Bodéré, Francoise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2019-09</date><risdate>2019</risdate><volume>79</volume><issue>13</issue><spage>1514</spage><epage>1522</epage><pages>1514-1522</pages><issn>0270-4137</issn><issn>1097-0045</issn><eissn>1097-0045</eissn><abstract>In this prospective study (NCT03443609), we investigated the impact of 68Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response obtained for patients with prostate cancer (PCa) presenting a recurrence with a low rising PSA.
One hundred thirty hormone-naive (PSA < 1.5 ng/mL) patients were enrolled. All patients received radical treatment. PET images were recorded 1 and 2 hours after injection of tracer and interpreted by two independent nuclear physicians. Six months after treatment ended, a PSA assay was requested to evaluate the therapeutic efficacy of the treatment based on PSMA results.
Data analysis for the first 52 included patients has been completed. 68Ga-PSMA-11-positive lesions were detected in 38/52 (73.1%) patients. Ninety-four lesions were detected as follows, 53/94 in lymph nodes (56.4%), 25/94 in bone (26.6%), and 12/94 into the prostate bed (12.7%). Detection rates were 58%, 81%, and 82% for serum PSA levels lower than 0.25 ng/mL, between 0.25 to ≤ 0.69 ng/mL and 0.70 ng/mL, respectively. As a result of the PSMA PET-CT, therapeutic management changed in 38/52 patients (73.1%). Patients had undetectable serum PSA levels after treatment guided by 68Ga-PSMA-11 PET-CT results in 10/52 (19.2%) cases and with a PSA decrease of over 60% in 18/52 (34.6%) patients.
Whilst our patient population presented a very low PSA level, preliminary results of the 68Ga-PSMA PET-CT study showed recurrence localization in more than half of the patients and this had a major clinical impact, as it resulted in treatment change in more than half of the patients and a significant decrease in PSA levels in a third of patients.</abstract><cop>United States</cop><pmid>31421657</pmid><doi>10.1002/pros.23869</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0455-0523</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2019-09, Vol.79 (13), p.1514-1522 |
| issn | 0270-4137 1097-0045 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2275319007 |
| source | Wiley |
| subjects | Aged Decision Making Gallium Isotopes Gallium Radioisotopes Humans Kallikreins - blood Male Membrane Glycoproteins Middle Aged Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - therapy Organometallic Compounds Positron Emission Tomography Computed Tomography - methods Prospective Studies Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - therapy Radiopharmaceuticals |
| title | Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A33%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20results%20of%20a%2068%20Ga-PSMA%20PET/CT%20prospective%20study%20in%20prostate%20cancer%20patients%20with%20occult%20recurrence:%20Diagnostic%20performance%20and%20impact%20on%20therapeutic%20decision-making&rft.jtitle=The%20Prostate&rft.au=Rousseau,%20Caroline&rft.date=2019-09&rft.volume=79&rft.issue=13&rft.spage=1514&rft.epage=1522&rft.pages=1514-1522&rft.issn=0270-4137&rft.eissn=1097-0045&rft_id=info:doi/10.1002/pros.23869&rft_dat=%3Cproquest_cross%3E2275319007%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1327-a177219c2547d6269e4b96d808c06f891d9b64d8eac9b9a814179dab374e459c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2275319007&rft_id=info:pmid/31421657&rfr_iscdi=true |